Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism
Status:
Completed
Trial end date:
2018-05-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of BGS649 in male obese
subjects with hypogonadotropic hypogonadism. All subjects will be treated for a maximum of 24
weeks. Some subjects who complete 24 weeks of treatment will be invited to participate in a
6-month blinded safety extension study (Protocol MBGS206). The study is planned to enroll 268
subjects.